Loading
Immunologist who built individualised mRNA neoantigen vaccines for cancer, the platform later used for COVID-19.
Uğur Şahin led the 2017 Nature trial showing individualised mRNA vaccines encoding each patient's mutations induce T-cell responses in melanoma, the proof of concept for personalised cancer vaccines now in phase 2 and 3 trials with autogene cevumeran in pancreatic and colorectal cancer. He co-founded BioNTech with Özlem Türeci and continues academic work in Mainz on mRNA, CAR-T and bispecific therapies.
The strongest human evidence that a cancer vaccine can make durable T cells in a tumour with few mutations; the randomised phase 2 IMCODE003 (260 patients, primary completion listed for January 2031) is the test of whether that translates into fewer relapses.
Pancreatic cancer was thought to be immunologically inert because of its low mutation burden; this study showed that with the right vaccine platform its few neoantigens can still be targeted. It is the strongest human evidence so far that personalised cancer vaccines can generate durable, tumour-specific immunity, and it justifies the randomised trials now running in pancreatic cancer and melanoma. Benefit is not yet proven, because responders may simply have had more immunogenic tumours.
Shares RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer, Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer, Autogene cevumeran, Personalised neoantigen (mRNA) vaccines and the tags vaccine, immunotherapy.
Shares Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer, Autogene cevumeran, Personalised neoantigen (mRNA) vaccines, Melanoma.
Shares RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer, Autogene cevumeran, Personalised neoantigen (mRNA) vaccines, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares Personalised neoantigen (mRNA) vaccines, Melanoma and the tag vaccine.
Shares Autogene cevumeran, Personalised neoantigen (mRNA) vaccines, Melanoma, Pancreatic ductal adenocarcinoma.
Shares Autogene cevumeran, Personalised neoantigen (mRNA) vaccines, Melanoma, Pancreatic ductal adenocarcinoma.
Shares Personalised neoantigen (mRNA) vaccines, Melanoma and the tag vaccine.
Shares Melanoma and the tag immunotherapy.